Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer

Fig. 1

Study design. Note: Most patients at the Cross Cancer Institute will receive three anthracycline cycles total, followed by additional chemotherapy treatments (typically taxanes). In the case where patients receive more than three anthracycline treatments, the intervention will be applied to all cycles received

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us